A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Vertex Pharmaceuticals Incorporated120 enrolled

Overview

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

120

Conditions

Rheumatoid Arthritis

Interventions

VX-702DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients 18 to 75 years of age with active RA * Must have been taking MTX for at least 6 months * No concurrent DMARD treatment (other than a stable dose of MTX) Exclusion Criteria: * Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study * Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1

Locations (17)

Call For Information

Dimitrovgrad, Bulgaria

Call For Information

Pleven, Bulgaria

Call For Information

Sofia, Bulgaria

Outcomes

Primary Outcomes

To evaluate the effects of VX-702 administered with concomitant methotrexate (MTX), and MTX alone

Secondary Outcomes

To evaluate the safety and tolerability of VX-702 administered with concomitant MTX, and MTX alone

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.